We closed the third quarter with continued momentum—advancing our clinical programs, sharing new scientific insights, and preparing for what’s ahead.

Read our latest corporate update and Q3 2025 financial results: ir.newamsterdampharma.com/news-release...

Even when taking statins, many ASCVD patients face residual cardiovascular risk.

We’re excited to see our Alzheimer’s disease biomarker data from a prespecified substudy in our BROADWAY clinical trial has been peer-reviewed and published in the Journal of Prevention of Alzheimer’s Disease. 🔓 Read the open access article: www.newamsterdampharma.com/wp-content/u...

Despite being on lipid-lowering therapies, many patients still have LDL-C levels above recommended targets. This LDL-C Awareness Day, take a moment for your health—talk to your doctor and see if it's time for a cholesterol check.

Nimble, agile, and locked in with our patient focus. Our Chief Commercial Officer BJ Jones shares some of what makes our culture unique, from having a still-practicing clinician as CEO, to the clarity of our shared mission.

Learn more about us: www.newamsterdampharma.com/aboutus?utm_...

Addressing cholesterol dysregulation in the brain may help delay the formation of amyloid plaque and tau tangle buildup that contributes to Alzheimer’s disease. Explore the science: bit.ly/42naX4D

Prof Stephen Nicholls shared major adverse cardiovascular event (MACE) outcomes based on an analysis of pooled data from our Phase 3 BROOKLYN & BROADWAY studies of our investigational drug therapy, obicetrapib. The data were also simultaneously published in @jaccjournals.bsky.social: bit.ly/4mHrXeb

Tomorrow at #ESCCongress, Professor Kausik Ray will discuss data on our investigational CETP inhibitor as an add-on to background lipid-lowering therapies in a pooled analysis of our BROADWAY and BROOKLYN trials. esc365.escardio.org/esc-congress...